Due to the current lack of a suitable compound to suppress astrocytic ET-1 production we have started a phase 2 trial in MS patients with the ET-1 receptor antagonist bosentan (Hostenbach et al., 2019). Here, EDN1 is linked to myeloid sarcoma.